Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 May;189(3):452-468.
doi: 10.1111/bjh.16408. Epub 2020 Feb 19.

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years

Stéphanie Dulucq  1   2 , Cyril Astrugue  3   4 , Gabriel Etienne  2   5 , François-Xavier Mahon  2   5 , Antoine Benard  3   4
Affiliations
Meta-Analysis

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years

Stéphanie Dulucq et al. Br J Haematol. 2020 May.

Abstract

More than 10 years ago, the first pilot observational study of imatinib discontinuation was reported in chronic myeloid leukaemia (CML) patients in deep molecular response (DMR). Several studies have been published since then, in patients treated with frontline imatinib, or second-generation tyrosine kinase inhibitors (TKI) in first or second line but also on second attempt of TKI discontinuation. Our objective was to estimate, through meta-analyses of the literature data, the probability of molecular recurrence (MolRec) in the time periods of 0-6, 6-12, 12-18 and 18-24 months after a first and second TKI discontinuation and the probability of re-acquisition of DMR after MolRec. The Medline and Scopus databases were searched up to April 2019. The studies were selected by three independent reviewers. Random-effect meta-analyses were conducted using the MetaXL software. The probability of MolRec in the time periods 0-6, 6-12, 12-18 and 18-24 months after the first attempt was respectively 35%, 8%, 3% and 3%, whereas the probability of MolRec in the time periods 0-6, 6-12 and 12-18 after the second attempt was 48%, 27% and 12% respectively. Re-acquisition of a DMR was observed in 90% of patients. Most of the MolRec occur during the first six months in case of a first attempt, whereas the second MolRec occurs over a larger window of time.

Keywords: chronic myeloid leukemia; first and second attempt; meta-analysis; tyrosine kinase inhibitors discontinuation.

PubMed Disclaimer

References

    1. Campiotti, L., Suter, M.B., Guasti, L., Piazza, R., Gambacorti-Passerini, C., Grandi, A.M. & Squizzato, A. (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. European Journal of Cancer (Oxford, England: 1990), 77, 48-56.
    1. Cerveira, N., Loureiro, B., Bizarro, S., Correia, C., Torres, L., Lisboa, S., Vieira, J., Santos, R., Pereira, D., Moreira, C., Chacim, S., Domingues, N., Espírito-Santo, A., Oliveira, I., Moreira, I., Viterbo, L., Martins, Â., Teixeira, M.R. & Mariz, J.M. (2018) Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer, 18, 1245.
    1. Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G.N., Issa, G.C., Rios, M.B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., Daver, N., Konopleva, M., DiNardo, C.D., Kadia, T., Pemmaraju, N., Jabbour, E. & Cortes, J. (2019) Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology & Oncology, 12, 1.
    1. Chen, K.-K., Du, T.-F., Xiong, P.-S., Fan, G.-H. & Yang, W. (2019) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Frontiers in Oncology, 9, 372.
    1. Clark, R.E., Polydoros, F., Apperley, J.F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., O’Brien, S.G., Read, L., Foroni, L. & Copland, M. (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6, e375-e383.

Publication types

Substances

LinkOut - more resources